首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >ASSESSMENT OF LIFE QUALITY IN PATIENTS WITH STAGE IIB-IIIB SQUAMOUS CELL CERVICAL CANCER RECEIVING PACLITAXEL CISPLATIN CHEMOTHERAPY REGIMEN BY EORTC QLQ-C30 QUESTIONNAIRE IN SANGLAH HOSPITAL DENPASAR
【24h】

ASSESSMENT OF LIFE QUALITY IN PATIENTS WITH STAGE IIB-IIIB SQUAMOUS CELL CERVICAL CANCER RECEIVING PACLITAXEL CISPLATIN CHEMOTHERAPY REGIMEN BY EORTC QLQ-C30 QUESTIONNAIRE IN SANGLAH HOSPITAL DENPASAR

机译:EORTC QLQ-C30问卷在桑格拉医院登巴萨的IIB-IIIB期鳞状细胞癌宫颈癌患者接受帕西他赛半胱氨酸化疗方案的患者的生活质量评估

获取原文
           

摘要

Objective: Cervical cancer was the prominent cause of women's death in developing states. Decrease in life quality was often encountered by patients with cervical cancer in advanced stages. One treatment method of cervical cancer at Sanglah Hospital was using paclitaxel cisplatin chemotherapy. Information on cervical cancer patient's life quality who received paclitaxel cisplatin chemotherapy was still limited, so research was required to observe cervical cancer patients’ life quality before the first and after the sixth paclitaxel cisplatin chemotherapy regimen. Method s : Observational study with prospective case study design was undertaken at the Polyclinic of Obstetrics and Gynecology Sanglah Hospital from January to August 2016. Sampling was conducted before chemotherapy I and after chemotherapy VI using consecutive sampling method. The EORTC QLQ C30 questionnaires were completed by the patients before chemotherapy I and after chemotherapy VI. Patients' life quality who had received paclitaxel cisplatin chemotherapy were assessed with 15 domains in EORTC QLQ C30 questionnaire. The data obtained were processed with STATA ? version 14 and analysed using paired t test and Wilcoxon test with a confidence level of 95%. Result s : The number of sample s used in this study was 7 patients who received paclitaxel cisplatin chemotherapy. The results of the analysis showed that there were differences in cervical cancer patients’ life quality who had received paclitaxel cisplatin regimen chemotherapy before chemotherapy I and after chemotherapy VI with the result of p-value is 0.0005. Conclusion: There was a significant decrease in the value of cervical cancer patients' life quality who received paclitaxel cisplatin chemotherapy before chemotherapy I and after chemotherapy VI.
机译:目的:宫颈癌是发展中国家女性死亡的主要原因。宫颈癌晚期患者常常会降低生活质量。 Sanglah医院的一种子宫颈癌治疗方法是使用紫杉醇顺铂化疗。接受紫杉醇顺铂化疗的宫颈癌患者生活质量的信息仍然有限,因此需要进行研究以观察宫颈癌患者在第一,第六次紫杉醇顺铂化疗方案之前和之后的生活质量。方法s:2016年1月至2016年8月在Sanglah妇产科综合诊所进行了具有前瞻性案例研究设计的观察性研究。采用连续采样的方法在化疗I之前和化疗VI之后进行采样。 EORTC QLQ C30问卷由患者在化疗前I和化疗后VI完成。接受紫杉醇顺铂化疗的患者生活质量通过EORTC QLQ C30问卷中的15个域进行评估。获得的数据用STATA®处理。版本14,并使用配对t检验和Wilcoxon检验进行分析,置信度为95%。结果:本研究使用的样本数为7例接受了紫杉醇顺铂化疗的患者。分析结果表明,接受紫杉醇顺铂方案化疗的宫颈癌患者在化疗前和化疗后的生活质量存在差异,p值为0.0005。结论:化疗I和化疗VI后接受紫杉醇顺铂化疗的宫颈癌患者生活质量价值显着降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号